Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Song Ren

Showing results (111-120 of 156) with videos related to

Pageof 16
Sort By:
Frontiers in Pharmacology|April 12, 2018
Erzhi Pill<sup>®</sup> Protected Experimental Liver Injury Against Apoptosis via the PI3K/Akt/Raptor/Rictor PathwayHai-Mei Zhao, Xiao-Yun Zhang, Xiu-Yun Lu, et al.
Journal of Biotechnology|October 15, 2005
Biochemical properties of C78SC96S rhFGF-2: a double point-mutated rhFGF-2 increases obviously its activityJu Wang, An Hong, Jin-Song Ren, et al.
Clinical Colorectal Cancer|September 5, 2016
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal AdenocarcinomasMichael Pishvaian, Michael A Morse, Jennifer McDevitt, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 18, 2013
Index-based dietary patterns and risk of esophageal and gastric cancer in a large cohort studyWen-Qing Li, Yikyung Park, Jennifer W Wu, et al.
International Journal of Immunopathology and Pharmacology|December 21, 2021
Splenic CD4<sup>+</sup> and CD8<sup>+</sup> T-cells highly expressed PD-1 and Tim-3 in cirrhotic patients with HCV infection and portal hypertensionNa Huang, Rui Zhou, Haiyan Chen, et al.
Chinese Medical Journal|July 26, 2021
Risk factors for gastric cancer: a large-scale, population-based case-control studyRui Zhang, He Li, Ni Li, et al.
Cancer Chemotherapy and Pharmacology|January 17, 2025
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancerAburough Abegesah, Do-Youn Oh, KyoungSoo Lim, et al.
Journal of Clinical Pharmacology|June 10, 2023
Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular CarcinomaKyoungSoo Lim, Aburough Abegesah, Chunling Fan, et al.
The International Journal of Biochemistry & Cell Biology|August 30, 2014
Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cellsBaofeng Wang, Baohua Li, Zhijun Dai, et al.
Cancer Management and Research|August 9, 2020
Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005-2014) Retrospective StudyPu-Yuan Xing, Shou-Zheng Wang, Ju-Fang Shi, et al.
Pageof 16

Showing results (111-120 of 156) with videos related to

Sort By:
Pageof 16
Frontiers in Pharmacology|April 12, 2018
Erzhi Pill<sup>®</sup> Protected Experimental Liver Injury Against Apoptosis via the PI3K/Akt/Raptor/Rictor PathwayHai-Mei Zhao, Xiao-Yun Zhang, Xiu-Yun Lu, et al.
Journal of Biotechnology|October 15, 2005
Biochemical properties of C78SC96S rhFGF-2: a double point-mutated rhFGF-2 increases obviously its activityJu Wang, An Hong, Jin-Song Ren, et al.
Clinical Colorectal Cancer|September 5, 2016
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal AdenocarcinomasMichael Pishvaian, Michael A Morse, Jennifer McDevitt, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 18, 2013
Index-based dietary patterns and risk of esophageal and gastric cancer in a large cohort studyWen-Qing Li, Yikyung Park, Jennifer W Wu, et al.
International Journal of Immunopathology and Pharmacology|December 21, 2021
Splenic CD4<sup>+</sup> and CD8<sup>+</sup> T-cells highly expressed PD-1 and Tim-3 in cirrhotic patients with HCV infection and portal hypertensionNa Huang, Rui Zhou, Haiyan Chen, et al.
Chinese Medical Journal|July 26, 2021
Risk factors for gastric cancer: a large-scale, population-based case-control studyRui Zhang, He Li, Ni Li, et al.
Cancer Chemotherapy and Pharmacology|January 17, 2025
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancerAburough Abegesah, Do-Youn Oh, KyoungSoo Lim, et al.
Journal of Clinical Pharmacology|June 10, 2023
Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular CarcinomaKyoungSoo Lim, Aburough Abegesah, Chunling Fan, et al.
The International Journal of Biochemistry & Cell Biology|August 30, 2014
Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+Treg cellsBaofeng Wang, Baohua Li, Zhijun Dai, et al.
Cancer Management and Research|August 9, 2020
Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005-2014) Retrospective StudyPu-Yuan Xing, Shou-Zheng Wang, Ju-Fang Shi, et al.
Pageof 16